SCHEMBL24927353

SCHEMBL24927353

CCCC(C)(C)NS(=O)(=O)c1cccc(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DUT P33316 3/20 0.56
KEAP1 Q14145 2/20 0.50
NFE2L2 Q16236 2/20 0.50
MEP1B Q16820 1/20 0.50
FFAR4 Q5NUL3 1/20 0.50
PGR P06401 2/20 0.48
LMNA P02545 2/20 0.47
ALDH1A1 P00352 2/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.46
MTNR1B P49286 1/20 0.45
PTGES2 Q9H7Z7 1/20 0.45
RORA P35398 1/20 0.45
RORC P51449 1/20 0.45
NR1H2 P55055 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24926381 0.89 PARG (0.55) DUTKEAP1NFE2L2MEP1BFFAR4
SCHEMBL11209446 0.82 LMNA (0.65) DUTKEAP1NFE2L2MEP1BFFAR4
SCHEMBL20254153 0.79 ALDH1A1 (0.55) DUTALDH1A1KDM4EMAPTKMT2A
SCHEMBL24429468 0.78 CA1 (0.56) PGRLMNAALDH1A1POLBGAA
SCHEMBL24429435 0.77 ALDH1A1 (0.42) ALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL1822202 0.76 MEP1B (0.65) KEAP1NFE2L2MEP1BFFAR4PGR
SCHEMBL14676154 0.76 MEP1B (0.54) KEAP1NFE2L2MEP1BFFAR4PGR
SCHEMBL11157739 0.74 MEP1B (0.59) KEAP1NFE2L2MEP1BFFAR4PGR
SCHEMBL12561642 0.74 KEAP1 (0.62) KEAP1NFE2L2MEP1BFFAR4PGR
SCHEMBL29909928 0.74 KEAP1 (0.62) KEAP1NFE2L2MEP1BFFAR4PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230031954-A1 TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT TETRAPHASE PHARMACEUTICALS, INC. 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230031954-A1 TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT MCL1, ABL1, MALT1 DUT 1858/4885KEAP1 2298/4885NFE2L2 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.